GlassScriptPhysician profile
Stephen Scott Bylsma
NPI 1265435325
$6,018.40
in general payments reported to CMS, 2019-2025
23 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $848 · 2020: $361 · 2021: $434 · 2022: $1,050 · 2023: $1,044 · 2024: $922 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,325.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,212.32 | 2019-2025 | Clareon, Lensx, Acrysof Iq Vivity |
| Abbvie INC. | $656.33 | 2022-2025 | Xen Glaucoma Treatment System, Durysta |
| Glaukos Corporation | $559.18 | 2019-2025 | Idose, Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Sight Sciences, INC. | $201.63 | 2020-2022 | |
| Amgen INC. | $175.74 | 2024-2025 | Tepezza |
| Allergan, INC. | $168.17 | 2020-2022 | |
| Ivantis, INC | $142.63 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $131.47 | 2019 | |
| Aerie Pharmaceuticals, INC. | $116.34 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $105.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $102.92 | 2019-2022 | |
| Biotissue Holdings INC. | $98.14 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $55.33 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $52.60 | 2023 | Rayone Spheric, Rayone Aspheric, Omidria |
| Dompe US, INC. | $51.31 | 2022-2024 | Oxervate |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $35.86 | 2024 | Vyzulta, Miebo |
| Optos, INC. | $31.27 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $24.92 | 2025 | Eylea Hd |
| Eyepoint US, INC. | $21.23 | 2019 | |
| Sun Pharmaceutical Industries INC. | $20.41 | 2023 | Cequa |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $19.16 | 2025 | Xdemvy |
| Horizon Therapeutics Plc | $16.43 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bylsma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.